# Quizartinib Maintenance Therapy

## INDICATIONS FOR USE:

| INDICATION | ICD10 | Regimen Code | HSE approved reimbursement status* |
|---|---|---|---|
| As monotherapy for the maintenance treatment of adult patients with *FLT3*-ITD mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy. | C92 | 00888a | CDS 01/02/2025 |

* This applies to post 2012 indications

## TREATMENT:

*The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances*

- Maintenance treatment is administered as per the treatment table below for up to a maximum of 36 cycles, following treatment with Quizartinib Induction and Consolidation Therapy.
    - **Induction: Ref NCCP Regimen 886 Quizartinib, DAUNOrubicin and Cytarabine Induction Therapy OR NCCP Regimen 891 Quizartinib, IDArubicin and Cytarabine Induction Therapy.**
    - **Consolidation: Ref NCCP Regimen 887 Quizartinib and Intermediate Dose Cytarabine Therapy.**
- Quizartinib Maintenance Therapy should begin after haematologic recovery (ANC **≥0.5 x$10^9$/L**, platelet count **≥50 x $10^9$/L**) from Consolidation Therapy.
- For patients who proceed to haematopoietic stem cell transplantation (HSCT), quizartinib should be stopped 7 days before the start of a conditioning regimen. It may be resumed after completion of the transplant based on white blood cell count (WBC) and at the discretion of the treating physician for patients with sufficient haematologic recovery and with ≤ Grade 2 graft-versus-host disease (GVHD), not requiring the initiation of new systemic GVHD therapy within 21 days, following the dosing recommendations.

Facilities to treat anaphylaxis MUST be present when systemic anti-cancer therapy (SACT) is administered.



The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer

*This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPSACTregimens*

| Day | Drug | Dose | Route | Cycle |
|---|---|---|---|---|
| 1-14 | Quizartinib[a, b, c] | 26.5mg once daily | PO | Cycle 1 initiation dose<br>***if QTcF is ≤450ms** |
| 15-28 | Quizartinib[a, b, c] | 53mg once daily | PO | Cycle 1<br>***if QTcF is ≤450ms after 14 day initiation dose** |
| 1-28 | Quizartinib[a, b, c] | 53mg once daily | PO | Cycle 2 onwards for up to 35 cycles |
| [a]Quizartinib tablets should be taken at approximately the same time each day with or without food.<br>Quizartinib tablets are commonly available as 17.7mg and 26.5 mg tablets | | | | |
| [b]If a dose of quizartinib is missed or not taken at the usual time, the patient should take the dose as soon as possible on the same day and return to the usual schedule the following day. The patient should not take two doses on the same day. | | | | |
| [c]If the patient vomits after taking quizartinib, the patient should not take an additional dose that day but take the next dose the following day at the usual time. | | | | |

Note: Administration volumes and fluids have been standardised to facilitate electronic prescribing system builds.

## ELIGIBILITY:

- Indication as above
- ECOG 0-2
- Newly diagnosed AML with FLT3 mutation confirmed using a validated test

## CAUTIONS:

- Patients who are at significant risk of developing QT interval prolongation including:
  - patients with uncontrolled or significant cardiovascular disease,
  - myocardial infarction within 6 months,
  - uncontrolled angina pectoris,
  - uncontrolled hypertension,
  - congestive heart failure,
  - history of clinically relevant ventricular arrhythmias or torsade de pointes),
  - patients receiving concomitant medicinal products known to prolong the QT interval.

## EXCLUSIONS:

- Hypersensitivity to quizartinib or to any of the excipients
- Diagnosis of acute promyelocytic leukaemia (APL), French American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12) or BCR ABL positive leukaemia
- Congenital long QT syndrome
- QTcF interval >450 ms
- Severe renal or hepatic impairment
- Pregnancy
- Breastfeeding



The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer

*This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPSACTregimens*

## PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Haematologist working in the area of haematological malignancies.

## TESTS:

**Baseline tests:**

- FBC, renal and liver profile, potassium, magnesium
- ECG
- Pregnancy test within 7 days of starting treatment
- Hepatitis B virus (HBV) serology [HBV sAg, HBV sAb, HBV cAb], hepatitis C virus (HCV) serology, human immunodeficiency virus (HIV) serology, cytomegalovirus (CMV) serology [IgG] and additional screening as clinically indicated
  *Reference Regimen Specific Complications for information on Hepatitis B reactivation

**Regular tests:**

- FBC, renal and liver profile, potassium, magnesium
- ECG
  - once weekly for the first month following dose initiation and escalation, and thereafter as clinically indicated. The maintenance starting dose should not be escalated if the QTcF interval is greater than 450 ms.
  - Monitoring should be performed more frequently in patients who:
    - are at significant risk of developing QT interval prolongation and torsade de pointes or
    - if quizartinib is being used concomitantly with medicinal products known to prolong the QT interval or
    - if patients experience diarrhoea or vomiting

**Disease monitoring:**

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

## DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.



The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer

*This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPSACTregimens*

**Table 1: Dose adjustments for adverse reactions and/or concomitant use with strong CYP3A inhibitors during maintenance treatment with quizartinib**

| Maintenance Phase | Full dose | Dose reductions | | |
|---|---|---|---|---|
| | | Adverse reaction | Concomitant strong CYP3A inhibitors | Adverse reaction and concomitant strong CYP3A inhibitors |
| Day 1-14 | 26.5mg | Interrupt | 17.7mg | Interrupt |
| Day 14 onwards | 53mg | 35.4mg | 26.5mg | 17.7mg |

## Management of adverse events:

**Table 2: Dose Modification for Adverse Events**

| Adverse reaction | Recommended dose modification |
|---|---|
| QTcF 450-480 ms (Grade 1) | Continue quizartinib dose. |
| QTcF 481-500 ms (Grade 2) | • Reduce quizartinib dose (see Table 1) without interruption.<br>• Resume quizartinib at the previous dose in the next cycle if QTcF has decreased to < 450 ms. Monitor the patient closely for QT prolongation for the first cycle at the increased dose |
| QTcF ≥ 501 ms (Grade 3) | • Interrupt quizartinib.<br>• Resume quizartinib at a reduced dose (see Table 4) when QTcF returns to < 450 ms.<br>• Do not escalate to 53 mg once daily during maintenance if QTcF > 500 ms was observed during induction and/or consolidation, and it is suspected to be associated with quizartinib. Maintain the 26.5 mg once daily dose. |
| Recurrent QTcF ≥ 501 ms (Grade 3) | • Permanently discontinue quizartinib if QTcF > 500 ms recurs despite appropriate dose reduction and correction/elimination of other risk factors (e.g., serum electrolyte abnormalities, concomitant QT prolonging medicinal products). |
| Torsade de pointes; polymorphic ventricular tachycardia; signs/symptoms of life-threatening arrhythmia (Grade 4) | • Permanently discontinue quizartinib. |
| Grade 3 or 4 non-haematologic adverse reactions | • Interrupt quizartinib.<br>• Resume treatment at the previous dose if adverse reaction improves to ≤ Grade 1.<br>• Resume treatment at a reduced dose (see Table 1) if adverse reaction improves to < Grade 3.<br>• Permanently discontinue if Grade 3 or 4 adverse reaction persists beyond 28 days and is suspected to be associated with quizartinib |
| Persistent Grade 4 neutropenia or thrombocytopenia without active bone marrow disease | Reduce the dose (see Table 1) |

* Grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03).



The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer

*This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPSACTregimens*

## Renal and Hepatic Impairment:

**Table 3: Dose modification in renal and hepatic impairment**

| Drug | Renal Impairment | | Hepatic Impairment | |
|---|---|---|---|---|
| **Quizartinib** | **Mild/moderate** | No dose adjustment is recommended | **Mild/moderate** | No dose adjustment is recommended |
| | **Severe** | Not recommended for use in patients with severe renal impairment (CrCl < 30 mL/min, estimated by Cockcroft-Gault), as safety and efficacy have not been established in this population. | **Severe** | Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C), as safety and efficacy have not been established in this population |
| Quizartinib: Renal and hepatic - SmPC | | | | |

# SUPPORTIVE CARE:

## EMETOGENIC POTENTIAL:

- As outlined in NCCP Classification Document for Systemic AntiCancer Therapy (SACT) Induced Nausea and Vomiting Available on the NCCP website

**Quizartinib**: Moderate to high (**Refer to local policy).**

**For information:**
**Within NCIS regimens, antiemetics have been standardised by the Medical Oncologists and Haemato-oncologists and information is available in the following documents:**

- NCCP Supportive Care Antiemetic Medicines for **Inclusion in NCIS** (Medical Oncology) - Available on the NCCP website
- NCCP Supportive Care Antiemetic Medicines for **Inclusion in NCIS** (Haemato-oncology) - Available on the NCCP website

## PREMEDICATIONS: No specific recommendations

## OTHER SUPPORTIVE CARE:

- Tumour lysis syndrome prophylaxis **(Refer to local policy).**
- Proton pump Inhibitor **(Refer to local policy).**
- Anti-viral prophylaxis **(Refer to local policy).**
- Anti-fungal prophylaxis **(Refer to local policy).** Strong CYP3A4 inhibitors (e.g. posaconazole) can increase quizartinib exposure. If concomitant use is required, the dose of quizartinib should be reduced as per table 1.



The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer

*This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPSACTregimens*

## ADVERSE EFFECTS:

- Please refer to the relevant Summary of Product Characteristics (SmPC) for details.
- Quizartinib is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.

## REGIMEN SPECIFIC COMPLICATIONS

- **Hepatitis B Reactivation:** Patients should be tested for both HBsAg and HBcoreAb as per local policy. If either test is positive, such patients should be treated with anti-viral therapy **(Refer to local infectious disease policy).** These patients should be considered for assessment by hepatology.

## DRUG INTERACTIONS:

- Current SmPC and drug interaction databases should be consulted for information.

## REFERENCES:


1. Erba HP, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT£-internal-tandem-dubplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023. 13;401(10388):1571-1583.
2. Quizartinib (Vanflyta®) Summary of Product Characteristics. Last updated 05/02/2026. Accessed February 2026. Available at: https://www.ema.europa.eu/en/documents/product-information/vanflyta-epar-product-information_en.pdf


| Version | Date | Amendment | Approved By |
|---|---|---|---|
| 1 | 01/02/2025 | | NCCP Myeloid SACT CAG |
| 2 | 19/02/2026 | Regimen reviewed. | Dr Vitaliy Mykytiv |

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.



The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer

*This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPSACTregimens*